How many analysts rate AKRO as a “Buy” - Free Stock Review Backed By Experts - jammulinksnews.com
21 hours ago • Google News
Akero Therapeutics Inc (AKRO)
US$ 44.6599-0.27%
Price Chart
Key Statistics
Market Cap
$ 3.89B
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
537.19K
52W High
$ 58.40
52W Low
$ 21.34
Dividend Yield
0.00%
Beta
-0.15
Technicals
50-Day MA
51.7967
200-Day MA
40.9896
52 Week High
58.4
52 Week Low
21.34
About AKRO
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States.
Employees
69
Headquarters
South San Francisco, CA
CEO
Dr. Andrew Cheng M.D., Ph.D.
Latest News
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today - Yahoo Finance
2025-05-20 • Google News
Published on: 2025-07-28 16:41:21 - beatles.ru
5 days ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg